These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31496700)

  • 1. Intracellular nanoparticle delivery by oncogenic KRAS-mediated macropinocytosis.
    Liu X; Ghosh D
    Int J Nanomedicine; 2019; 14():6589-6600. PubMed ID: 31496700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploiting macropinocytosis for drug delivery into KRAS mutant cancer.
    Liu H; Qian F
    Theranostics; 2022; 12(3):1321-1332. PubMed ID: 35154489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CX-4945 (Silmitasertib) Induces Cell Death by Impairing Lysosomal Utilization in
    Lee DS; Han MW; Kang Y; Kim C; Lee S; Kim KP; Yoo C
    Anticancer Res; 2024 May; 44(5):1939-1946. PubMed ID: 38677763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gold Nanoparticles Inhibit Macropinocytosis by Decreasing KRAS Activation.
    Elechalawar CK; Rao G; Gulla SK; Patel MM; Frickenstein A; Means N; Roy RV; Tsiokas L; Asfa S; Panja P; Rao C; Wilhelm S; Bhattacharya R; Mukherjee P
    ACS Nano; 2023 May; 17(10):9326-9337. PubMed ID: 37129853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
    Mehta A; Dalle Vedove E; Isert L; Merkel OM
    Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer.
    Hanada K; Kawada K; Nishikawa G; Toda K; Maekawa H; Nishikawa Y; Masui H; Hirata W; Okamoto M; Kiyasu Y; Honma S; Ogawa R; Mizuno R; Itatani Y; Miyoshi H; Sasazuki T; Shirasawa S; Taketo MM; Obama K; Sakai Y
    Cancer Lett; 2021 Dec; 522():129-141. PubMed ID: 34543685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
    Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
    Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutically reprogrammed nutrient signalling enhances nanoparticulate albumin bound drug uptake and efficacy in KRAS-mutant cancer.
    Li R; Ng TSC; Wang SJ; Prytyskach M; Rodell CB; Mikula H; Kohler RH; Garlin MA; Lauffenburger DA; Parangi S; Dinulescu DM; Bardeesy N; Weissleder R; Miller MA
    Nat Nanotechnol; 2021 Jul; 16(7):830-839. PubMed ID: 33958764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitin-binding associated protein 2 regulates KRAS activation and macropinocytosis in pancreatic cancer.
    Xiong X; Rao G; Roy RV; Zhang Y; Means N; Dey A; Tsaliki M; Saha S; Bhattacharyya S; Dhar Dwivedi SK; Rao CV; McCormick DJ; Dhanasekaran D; Ding K; Gillies E; Zhang M; Yang D; Bhattacharya R; Mukherjee P
    FASEB J; 2020 Sep; 34(9):12024-12039. PubMed ID: 32692445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAS-Driven Macropinocytosis of Albumin or Dextran Reveals Mutation-Specific Target Engagement of RAS p.G12C Inhibitor ARS-1620 by NIR-Fluorescence Imaging.
    Sutton MN; Gammon ST; Muzzioli R; Pisaneschi F; Radaram B; Yang P; Piwnica-Worms D
    Mol Imaging Biol; 2022 Jun; 24(3):498-509. PubMed ID: 34905147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-content, full genome siRNA screen for regulators of oncogenic HRAS-driven macropinocytosis.
    Fennell M; Commisso C; Ramirez C; Garippa R; Bar-Sagi D
    Assay Drug Dev Technol; 2015 Sep; 13(7):347-55. PubMed ID: 26267765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS
    Hobbs GA; Der CJ
    Subcell Biochem; 2022; 98():205-221. PubMed ID: 35378710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In situ exploration of characteristics of macropinocytosis and size range of internalized substances in cells by 3D-structured illumination microscopy.
    Jin J; Shen Y; Zhang B; Deng R; Huang D; Lu T; Sun F; Xu S; Liang C
    Int J Nanomedicine; 2018; 13():5321-5333. PubMed ID: 30254437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcription Factor Eb Is Required for Macropinocytosis-Mediated Growth Recovery of Nutrient-Deprived Kras-Mutant Cells.
    Jeong S; Byun JK; Cho SJ; Chin J; Lee IK; Choi YK; Park KG
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30400219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs.
    Liu H; Sun M; Liu Z; Kong C; Kong W; Ye J; Gong J; Huang DCS; Qian F
    J Control Release; 2019 Feb; 296():40-53. PubMed ID: 30653981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A recombinantly tailored β-defensin that displays intensive macropinocytosis-mediated uptake exerting potent efficacy against K-Ras mutant pancreatic cancer.
    Du Y; Shang BY; Sheng WJ; Zhang SH; Li Y; Miao QF; Zhen YS
    Oncotarget; 2016 Sep; 7(36):58418-58434. PubMed ID: 27517152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic RAS isoforms show a hierarchical requirement for the guanine nucleotide exchange factor SOS2 to mediate cell transformation.
    Sheffels E; Sealover NE; Wang C; Kim DH; Vazirani IA; Lee E; M Terrell E; Morrison DK; Luo J; Kortum RL
    Sci Signal; 2018 Sep; 11(546):. PubMed ID: 30181243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimulating macropinocytosis of peptide-drug conjugates through DNA-dependent protein kinase inhibition for treating KRAS-mutant cancer.
    Kim HR; Park SJ; Cho YS; Moyo MK; Choi JU; Lee NK; Chung SW; Kweon S; Park J; Kim B; Ko YG; Yeo JH; Lee J; Kim SY; Byun Y
    J Control Release; 2024 Aug; 372():176-193. PubMed ID: 38880331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS Addiction Promotes Cancer Cell Adaptation in Harsh Microenvironment Through Macropinocytosis.
    Seguin L
    Subcell Biochem; 2022; 98():189-204. PubMed ID: 35378709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Oncogenic Changes in p53 and KRAS on Macropinocytosis and Ferroptosis in Colon Cancer Cells and Anticancer Efficacy of Niclosamide with Differential Effects on These Two Processes.
    Nguyen NT; Sennoune SR; Dharmalingam-Nandagopal G; Sivaprakasam S; Bhutia YD; Ganapathy V
    Cells; 2024 May; 13(11):. PubMed ID: 38891084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.